In these S6K1-overexpressed tumours, palbociclib monotherapy could not successfully downregulate the levels of cell cycle-related genes, such as p-Rb (P = 0.962) and cyclin D1 (P = 0.320). This evidence concerns the gene RPS6KB1 and neoplasm.